Entasis Therapeutics snags $31.9 mln
Waltham, Massachusetts-based Entasis Therapeutics, a developer of anti-infective products, has raised $31.9 million in funding. The investors were Pivotal bioVenture Partners, Sofinnova Ventures and TPG Biotech. In conjunction with the funding, Dr. Tracy Saxton, managing partner at Pivotal, Dr. Heather Behanna, a principal at Sofinnova, and Dr. Heather Preston, a partner at TPG, have been added to the Entasis board of directors.
5 September 2017•1 min read
